Molecular determinants of head and neck cancer /
Saved in:
| Edition: | Second edition. |
|---|---|
| Imprint: | Cham : Humana Press, 2018. |
| Description: | 1 online resource |
| Language: | English |
| Series: | Current cancer research Current cancer research. |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11690115 |
Table of Contents:
- Intro; Contents; Chapter 1: Overview: The Pathobiology of Head and Neck Cancer; References; Chapter 2: Targeting the ErbB Family in Head and Neck Cancer; 2.1 Introduction; 2.2 Regulation of EGFR and the ErbB Family in Normal Cells; 2.2.1 Ligand Binding and Dimerization: Activation of ErbB Proteins in Normal Cells; 2.2.2 ErbB Trafficking and Other Mechanisms to Limit EGFR Function in Normal Cells; 2.3 Causes and Consequences of Altered EGFR/ErbB Function in SCCHN; 2.3.1 Overexpression of EGFR and Its Ligands
- 2.4.3 Targeting Critical EGFR/ErbB Effectors2.4.4 EGFR/ErbB2 and Immunotherapy/Immune Response; 2.5 Mechanisms of Resistance to Anti-EGFR Therapies; 2.5.1 EGFR-Intrinsic Resistance; 2.5.2 Elevated Expression of ErbB Family Members; 2.5.3 VEGF Expression; 2.5.4 STAT3 Expression; 2.5.5 KRAS and PI3K Mutation; 2.5.6 Microenvironment; 2.5.7 Epigenetic Changes; 2.5.8 Other Factors; 2.6 Toxicity and Tolerance; 2.7 Conclusions and New Frontiers in Drug Discovery; References; Chapter 3: c-MET in Head and Neck Squamous Cell Carcinoma; 3.1 Introduction; 3.2 c-MET Structure and Normal Function
- 3.2.1 c-MET General Structure3.2.2 c-MET Ligand: HGF/SF; 3.2.3 c-MET Trafficking; 3.2.4 c-MET-Associated Signaling; 3.3 c-MET Critical Interactions and Functions; 3.3.1 c-MET and the Epidermal Growth Factor (EGF) Family of Receptors; 3.3.2 c-MET and SRC; 3.3.3 c-MET in Epithelial-to-Mesenchymal Transition (EMT); 3.4 Dysregulation of HGF/c-MET in HNSCC; 3.4.1 c-MET Overexpression and Amplification; 3.4.2 c-MET Mutation; 3.4.3 Microenvironment and HGF/SF; 3.5 Clinical Applications of HGF/c-MET-Targeted Therapy; 3.5.1 Foretinib; 3.5.2 Tivantinib; 3.5.3 Additional Small-Molecule Inhibitors